

Sr. No.	Chapters with contents	Page no.
1.	<p>Introduction</p> <ul style="list-style-type: none"> • Brain tumor • Current treatment approaches for brain tumor • Temozolomide • Lenalidomide • Limitations associated with chemotherapeutic agents • Barriers associated with Chemotherapy of Brain tumors • Nanoparticles as drug delivery platform for overcoming drawbacks of conventional therapy • Albumin based Nanocarriers • Surface modification of albumin nanoparticles for targeted delivery to brain tumor • Aims and objectives • Hypothesis • Plan of work • References 	1-14
2.	<p>Literature review</p> <ul style="list-style-type: none"> • Brain tumor • Current treatment approaches for brain tumor • Hurdles in drug delivery to brain • Circumventing barriers for effective drug delivery • Nanoparticles as drug delivery platform • Albumin based nanocarriers • Surface functionalization of Albumin nanoparticles for targeted drug delivery • Temozolomide • Lenalidomide (LND) 	15-72

	<ul style="list-style-type: none"> References 	
3.	Analytical method development <ul style="list-style-type: none"> Materials Equipments Preparation of reagents Estimation of TMZ by UV-visible spectrophotometry Estimation of TMZ in plasma by double salting out assisted liquid-liquid extraction high pressure liquid chromatography (SALLE-HPLC) HPLC method II Estimation of LND by UV-visible spectrophotometer Estimation of LND by Spectrofluorophotometer Estimation of HA and CS using CTAB turbidimetric method Estimation of Lactoferrin (Lf) using Bradford Assay Estimation of albumin (BSA) using Bradford protein assay Results and discussion References 	73-99
4.	Preformulation studies <ul style="list-style-type: none"> Confirmation of Drugs Drug excipient interaction study Stability assessment of TMZ in different solvents Results and discussion 	100-110
5.	Formulation development, optimization, characterization and evaluation of Temozolomide loaded BSA nanoparticles (TNPs) <ul style="list-style-type: none"> Materials Equipment Methods <ul style="list-style-type: none"> Preparation of temozolomide loaded BSA nanoparticles (TNPs) Preliminary optimization of process and formulation variables Optimization of TNPs using experimental design 	111-146

	<ul style="list-style-type: none"> ○ Establishment and analysis of design space ○ Lyophilization of albumin nanoparticles ○ Characterization of albumin nanoparticles ○ Evaluation of albumin nanoparticles ○ Stability studies ○ Statistical Data Analysis ● Results and discussion ● References 	
6.	<p>Surface modified TNPs (HA-TNPs and CS-TNPs): Optimization, characterization and evaluation</p> <ul style="list-style-type: none"> ● Materials ● Equipment ● Methods <ul style="list-style-type: none"> ○ Surface modification of TNPs with Hyaluronic acid (HA) ○ Surface modification of TNPs with Chondroitin sulphate (CS) ○ Optimization of surface modified TNPs (HA-TNPs) ○ Optimization of surface modified TNPs (CS-TNPs) ○ Lyophilization of surface modified TNPs (HA-TNPs and CS-TNPs) ○ Characterization of Surface modified TNPs (HA-TNPs and CS-TNPs) ○ Evaluation of Surface modified TNPs (HA-TNPs and CS-TNPs) ○ Bio-Interactions of Surface modified TNPs (HA-TNPs and CS-TNPs) ○ Stability studies ○ Statistical Data Analysis ● Results and discussion ● References 	147-176
7.	<p><i>In vitro</i> cell line studies of developed TNPs, HA-TNPs and CS-TNPs</p> <ul style="list-style-type: none"> ● Materials 	177-197

	<ul style="list-style-type: none"> • Equipments • Methods <ul style="list-style-type: none"> ○ Cell culture protocols ○ <i>In -vitro</i> BBB Passage Study ○ <i>In-vitro</i> cell viability assay ○ Cell cycle analysis ○ Cellular uptake study ○ Cellular uptake mechanism ○ Reactive oxygen species (ROS) generation study ○ Scratch assay • Results and discussion • References 	
8.	<p>Animal studies: Pharmacokinetic, biodistribution and toxicity studies of developed TNPs, HA-TNPs and CS-TNPs</p> <ul style="list-style-type: none"> • <i>In vivo</i> studies • <i>Materials</i> <ul style="list-style-type: none"> ○ Pharmacokinetic study ○ Biodistribution study ○ <i>In vivo</i> toxicity study • Results and discussion • References 	198-206
9.	<p>Lenalidomide loaded albumin nanoparticles (LNPs and Lf-LNPs): Formulation development, optimization, surface modification, characterization and evaluation</p> <ul style="list-style-type: none"> • Materials • Equipments • Methods <ul style="list-style-type: none"> ○ Preparation of lenalidomide loaded BSA nanoparticles (LNPs) ○ Optimization of LNPs by One Factor At a Time (OFAT) variable design 	207-238

	<ul style="list-style-type: none"> ○ Surface modification of LNPs with lactoferrin (Lf) and it's optimization ○ Lyophilization of LND loaded albumin nanoparticles (LNPs and Lf-LNPs) ○ Characterization of LND loaded albumin nanoparticles (LNPs and Lf-LNPs) ○ Evaluation of LND loaded albumin nanoparticles (LNPs and Lf-LNPs) ○ Bio-Interactions of Lf-LNPs ○ Stability studies ○ Statistical Data Analysis ● Results and discussion ● References 	
10.	<p><i>In vitro</i> cell line studies of developed LNPs and LF-LNPs</p> <ul style="list-style-type: none"> ● Materials ● Equipments ● Methods <ul style="list-style-type: none"> ○ Cell culture protocols ○ <i>In -vitro</i> BBB Passage Study ○ <i>In-vitro</i> cell viability assay ○ Cellular uptake study ○ Cellular uptake mechanism ○ Lactoferrin receptor targeting assay ○ Reactive oxygen species (ROS) generation study ○ Scratch assay ● Results and discussion ● References 	239-249
11.	<p><i>In vivo</i> anticancer activity of Lf-LNPs</p> <ul style="list-style-type: none"> ● Introduction ● Cell line 	250-256

	<ul style="list-style-type: none">• Ethical statement• Animals• Method• Statistical analysis• Result and discussion• References	
12.	Summary and conclusion	256-265